https://www.selleckchem.com/products/atn-161.html
However, treatment in this complex disease model did not extend lifespan, improve serological endpoints, or preserve renal function, indicating there are elements of pathophysiology not accessible to DNaseI in the NZBWF1 model. We conclude that a translational solution to the challenge of short half-life of DNaseI is AAV-mediated gene delivery and that this may be efficacious in treating disease where NETs are a dominant pathological mechanism.Repetitive mild traumatic brain injury (r-mTBI), commonly experienced by athletes and military
Like
Comment
Share
